¼¼°èÀÇ ÁßÀçÀû Á¾¾çÇÐ µð¹ÙÀ̽º ½ÃÀå
Interventional Oncology Devices
»óǰÄÚµå : 1768709
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 282 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,666,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ÁßÀçÀû Á¾¾çÇÐ µð¹ÙÀ̽º ½ÃÀåÀº 2030³â±îÁö 39¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 27¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ÁßÀçÀû Á¾¾çÇÐ µð¹ÙÀ̽º ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 6.4%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 39¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ »öÀü ±â±â´Â CAGR 7.3%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 24¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀýÁ¦ µð¹ÙÀ̽º ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ÀÇ CAGR·Î 5.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 7¾ï 410¸¸ ´Þ·¯, Áß±¹Àº CAGR 9.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÁßÀçÀû Á¾¾çÇÐ µð¹ÙÀ̽º ½ÃÀåÀº 2024³â¿¡ 7¾ï 410¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGR 9.6%¸¦ °ßÀÎÇϸç, 2030³â¿¡´Â ¿¹Ãø ½ÃÀå ±Ô¸ð 9¾ï 1,560¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.4%¿Í 5.7%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÁßÀçÀû Á¾¾çÇÐ µð¹ÙÀ̽º ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÁßÀçÀû Á¾¾çÇÐ ±â±â´Â ¾î¶»°Ô ¾Ï Ä¡·á¸¦ ÁøÇàÇϰí Àִ°¡?

ÁßÀçÀû Á¾¾çÇÐ ±â±â´Â ±âÁ¸ ¼ö¼úÀÇ Çʿ伺À» ÁÙÀ̰í ÁÖº¯ Á¶Á÷ ¼Õ»óÀ» ÃÖ¼ÒÈ­Çϸ鼭 Á¾¾çÀ» Á¤È®ÇÏ°Ô Ç¥ÀûÈ­ÇÒ ¼ö ÀÖ´Â ÃÖ¼Òħ½ÀÀû ¼ö¼úÀ» Á¦°øÇÔÀ¸·Î½á ¾Ï Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ÀÌ ÀåºñµéÀº ¹æ»ç¼± ¼ÒÀÛ¿ä¹ý(RFA), ¸¶ÀÌÅ©·ÎÆÄ ¼ÒÀÛ¿ä¹ý(MWA), °æµ¿¸ÆÈ­ÇлöÀü¼ú(TACE)°ú °°Àº ¿µ»óÀ¯µµ¼ú¿¡ »ç¿ëµÇ¾î Á¾¾ç¿¡ Á÷Á¢ Ç¥ÀûÄ¡·á¸¦ ½ÃÇàÇÕ´Ï´Ù. ÁßÀçÀû Á¾¾çÇÐ Ä¡·á´Â °£¾Ï, Æó¾Ï, ½ÅÀå¾Ï, °ñ¾Ï¿¡ Á¡Á¡ ´õ ¸¹ÀÌ Àû¿ëµÇ°í ÀÖÀ¸¸ç, °³º¹¼ö¼ú¿¡ ´ëÇÑ ´ë¾ÈÀ¸·Î ȯÀÚ¿¡°Ô º¸´Ù ¾ÈÀüÇÏ°í ´ú ħ½ÀÀûÀÎ Ä¡·á¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº »ýÁ¸À²À» ³ôÀ̰í, ȸº¹ ½Ã°£À» ´ÜÃàÇϸç, ±âÁ¸ ¼ö¼úÀÌ ÀûÇÕÇÏÁö ¾ÊÀº ȯÀڵ鿡°Ô »õ·Î¿î Èñ¸ÁÀ» °¡Á®´ÙÁÖ°í ÀÖ½À´Ï´Ù.

ÁßÀçÀû Á¾¾çÇÐÀº ¾î¶² ±â¼ú Çõ½ÅÀÌ ÁÖµµÇϰí Àִ°¡?

MRI, CT, ÃÊÀ½ÆÄ µî ¿µ»ó±â¼úÀÇ Çõ½ÅÀº Ä¡·á ÁßÀÎ Á¾¾çÀ» ½Ç½Ã°£À¸·Î °íÇØ»óµµ·Î º¼ ¼ö ÀÖ°Ô ÇÏ¿© Ä¡·áÀÇ Á¤È®¼º°ú ¾ÈÀü¼ºÀ» Çâ»ó½Ã۰í, Ä¡·á Áß Á¾¾çÀ» ½Ç½Ã°£À¸·Î º¼ ¼ö ÀÖ°Ô ÇÏ¿© Ä¡·áÀÇ Á¤È®¼º°ú ¾ÈÀü¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ·Îº¿ ½Ã½ºÅÛÀº ÀÎÅͺ¥¼ÇÀÇ Á¤È®µµ¸¦ ³ôÀ̰í, ¼ÕÀÌ ´ê±â ¾î·Á¿î ºÎÀ§ÀÇ Á¾¾çÀ» º¸´Ù Á¤È®ÇÏ°Ô Æ÷ÂøÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ¸¶ÀÌÅ©·ÎÆÄ ¼ÒÀÛ¼ú°ú ³Ãµ¿ ¼ÒÀÛ¼úÀ» Æ÷ÇÔÇÑ »õ·Î¿î ¼ÒÀÛ ±â¼úÀº Á¤»ó Á¶Á÷¿¡ ´ëÇÑ ¼Õ»óÀ» ÃÖ¼ÒÈ­Çϸ鼭 Á¾¾çÀ» ÆÄ±«ÇÏ´Â º¸´Ù È¿°úÀûÀÎ ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ÁßÀçÀû Á¾¾çÇÐÀÇ ¿ª·®À» È®ÀåÇÏ¿© º¸´Ù ±¤¹üÀ§ÇÑ ¾ÏÀ» Ä¡·áÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­´Â ÁßÀçÀû Á¾¾çÇÐ ÀåºñÀÇ ¼ºÀåÀ» ¾î¶»°Ô Á¤ÀÇÇϴ°¡?

Àåºñ À¯Çü¿¡´Â ÀýÁ¦ Àåºñ, »öÀü ±â±â, »öÀü ±â±â, ÁöÁö Àåºñ°¡ ÀÖÀ¸¸ç, ÀýÁ¦ Àåºñ´Â Àúħ½ÀÀû Á¾¾ç ÆÄ±«¿¡ ³Î¸® »ç¿ëµÇ¾î ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. ½Ã¼ú¿¡´Â ¹æ»ç¼± ¼ÒÀÛ¿ä¹ý, ¸¶ÀÌÅ©·ÎÆÄ ¼ÒÀÛ¿ä¹ý, °æµ¿¸Æ È­ÇлöÀü¼úÀÌ Æ÷ÇԵǸç, ¸¶ÀÌÅ©·ÎÆÄ ¼ÒÀÛ¿ä¹ýÀº ´õ Å« Á¾¾çÀÇ Ä¡·á¿¡ ³ôÀº È¿°ú¸¦ º¸¿© Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ÁßÀçÀû Á¾¾çÇÐ Àåºñ·Î Ä¡·áµÇ´Â ¾Ï À¯Çü¿¡´Â °£¾Ï, Æó¾Ï, ½ÅÀå¾Ï, °ñ¾Ï µîÀÌ ÀÖÀ¸¸ç, °£¼¼Æ÷¾ÏÀÇ ³ôÀº À¯º´·ü·Î ÀÎÇØ °£¾ÏÀÌ °¡Àå Å« ºÎ¹®À» Çü¼ºÇϰí ÀÖ½À´Ï´Ù. ºÏ¹Ì¿Í À¯·´ µîÀÇ Áö¿ª¿¡¼­´Â ³ôÀº ¼öÁØÀÇ ÀÇ·á ÀÎÇÁ¶ó°¡ ±¸ÃàµÇ¾î ÀÖ°í Àúħ½ÀÀû Ä¡·áÀÇ µµÀÔÀÌ È°¹ßÈ÷ ÀÌ·ç¾îÁö°í ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

ÁßÀçÀû Á¾¾çÇÐ ±â±â ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

ÁßÀçÀû Á¾¾çÇÐ ±â±â ½ÃÀåÀÇ ¼ºÀåÀº ¾Ï ¹ßº´·ü Áõ°¡, ÃÖ¼Òħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, ¿µ»ó ¹× ÀýÁ¦ ±â¼úÀÇ ¹ßÀü µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ¾Ï ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó º¸´Ù ÃÖ¼Òħ½ÀÀûÀ̰í Ç¥ÀûÈ­µÈ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÁßÀçÀû Á¾¾çÇÐÀº ȯÀÚ¿¡°Ô ´ú ¿Ü»óÀûÀ̰í ȸº¹ÀÌ ºü¸¥ ½Ã¼úÀ» Á¦°øÇÔÀ¸·Î½á ÇØ°áÃ¥À» Á¦½ÃÇÒ ¼ö ÀÖ½À´Ï´Ù. ½Ç½Ã°£ ¿µ»ó ¹× Á¤¹Ð ÀýÁ¦¼úÀÇ Çõ½ÅÀº ÀÌ·¯ÇÑ Ä¡·áÀÇ È¿°ú¿Í ¾ÈÀü¼ºÀ» Çâ»ó½ÃÅ´À¸·Î½á ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·á ÀÎÇÁ¶óÀÇ °³¼±°ú ÷´Ü ÀÇ·á ±â¼ú¿¡ ´ëÇÑ Á¢±Ù¼º Çâ»ó¿¡ ÈûÀÔ¾î ½ÅÈï ½ÃÀå¿¡¼­ ÁßÀçÀû Á¾¾çÇÐÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

µð¹ÙÀ̽º(»öÀü µð¹ÙÀ̽º, ÀýÁ¦ µð¹ÙÀ̽º, Áö¿ø µð¹ÙÀ̽º), ¾ÏÁ¾(°£¾Ï, À¯¹æ¾Ï, Æó¾Ï, ½ÅÀå¾Ï, Àü¸³¼±¾Ï, ±âŸ ¾ÏÁ¾)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Interventional Oncology Devices Market to Reach US$3.9 Billion by 2030

The global market for Interventional Oncology Devices estimated at US$2.7 Billion in the year 2024, is expected to reach US$3.9 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Embolization Devices, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the Ablation Devices segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$704.1 Million While China is Forecast to Grow at 9.6% CAGR

The Interventional Oncology Devices market in the U.S. is estimated at US$704.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$915.6 Million by the year 2030 trailing a CAGR of 9.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Interventional Oncology Devices Market - Key Trends and Drivers Summarized

How Are Interventional Oncology Devices Advancing Cancer Treatment?

Interventional oncology devices are revolutionizing cancer treatment by offering minimally invasive procedures that target tumors with precision, reducing the need for traditional surgery and minimizing damage to surrounding tissues. These devices are used in image-guided procedures such as radiofrequency ablation (RFA), microwave ablation (MWA), and transarterial chemoembolization (TACE), which deliver targeted therapies directly to tumors. Interventional oncology treatments are increasingly being adopted for liver, lung, kidney, and bone cancers, providing patients with safer, less invasive alternatives to open surgery. These technologies are improving survival rates, reducing recovery times, and offering new hope to patients who may not be candidates for traditional surgery.

What Technological Innovations Are Driving Interventional Oncology?

Technological advancements in imaging modalities, robotics, and ablation techniques are driving the growth of interventional oncology. Innovations in imaging technologies, such as MRI, CT, and ultrasound, are enabling real-time, high-resolution visualization of tumors during procedures, improving the accuracy and safety of treatments. Robotic systems are enhancing the precision of interventions, allowing for better targeting of tumors in hard-to-reach areas. New ablation techniques, including microwave ablation and cryoablation, are providing more effective options for tumor destruction while minimizing damage to healthy tissues. These advancements are expanding the capabilities of interventional oncology and allowing for the treatment of a broader range of cancers.

How Do Market Segments Define the Growth of Interventional Oncology Devices?

Device types include ablation devices, embolization devices, and support devices, with ablation devices leading the market due to their widespread use in minimally invasive tumor destruction. Procedures include radiofrequency ablation, microwave ablation, and transarterial chemoembolization, with microwave ablation gaining popularity due to its higher efficacy in treating larger tumors. Cancer types treated with interventional oncology devices include liver, lung, kidney, and bone cancers, with liver cancer being the largest segment due to the high prevalence of hepatocellular carcinoma. The market is growing significantly in regions such as North America and Europe, driven by the availability of advanced healthcare infrastructure and the increasing adoption of minimally invasive treatments.

What Factors Are Driving the Growth in the Interventional Oncology Devices Market?

The growth in the interventional oncology devices market is driven by several factors, including the increasing incidence of cancer, the growing preference for minimally invasive treatments, and advancements in imaging and ablation technologies. As cancer rates rise globally, demand for less invasive and more targeted treatment options is increasing. Interventional oncology offers a solution by providing procedures that are less traumatic for patients and offer faster recovery times. Technological innovations in real-time imaging and precision ablation are further driving market growth by improving the effectiveness and safety of these treatments. Additionally, the rising adoption of interventional oncology in emerging markets, driven by improving healthcare infrastructure and access to advanced medical technologies, is contributing to the expansion of the market.

SCOPE OF STUDY:

The report analyzes the Interventional Oncology Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Device (Embolization Devices, Ablation Devices, Support Devices); Cancer Type (Liver Cancer, Breast Cancer, Lung Cancer, Kidney Cancer, Prostate Cancer, Other Cancer Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â